<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577651</url>
  </required_header>
  <id_info>
    <org_study_id>A4092</org_study_id>
    <nct_id>NCT04577651</nct_id>
  </id_info>
  <brief_title>Cartesia eXTend 3D Study</brief_title>
  <acronym>eXTend 3D</acronym>
  <official_title>Study to Evaluate Boston Scientific Vercise Cartesia 16-contact Directional Lead (X/HX) With Deep Brain Stimulation (DBS) Systems for the Treatment of Parkinson's Disease (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to document patient outcomes including effectiveness for Boston&#xD;
      Scientific Corporation's Vercise Cartesia 16-contact Directional Lead(s) (X/HX) with Deep&#xD;
      Brain Stimulation (DBS) systems for the treatment of Parkinson's Disease (PD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive Deep Brain Stimulation with a 16-contact Directional Lead to treat&#xD;
      their Parkinson's Disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in motor function</measure>
    <time_frame>12 weeks post device-activation</time_frame>
    <description>Mean change in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating (MDS-UPDRS) Part III scores from Baseline in meds off condition to 12 weeks post device-activation in stim on/meds off condition. Range 0 - 108. Higher scores indicate worse function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in motor function</measure>
    <time_frame>26 and 52 weeks post device-activation</time_frame>
    <description>Mean change in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating (MDS-UPDRS) Part III scores from Baseline (meds off) to 26 weeks and 52 weeks post device-activation (stim on/meds off). Range 0 - 108. Higher scores indicate worse function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>12, 26 and 52 weeks post device-activation</time_frame>
    <description>Mean change in Parkinson's Disease Questionnaire (PDQ-39) summary scores from Baseline (meds on) to 12 weeks, 26 weeks and 52 weeks post device-activation (stim on/meds on). Scores range from 0 to 100, with 0 representing perfect health and 100 representing worst health.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>16-contact Directional Deep Brain Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep Brain Stimulation with a 16-contact Directional Lead</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>16-contact Directional Deep Brain Stimulation</intervention_name>
    <description>Deep Brain Stimulation with 16-contact Directional Lead</description>
    <arm_group_label>16-contact Directional Deep Brain Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Candidate for DBS implant in the treatment of Parkinson's disease&#xD;
&#xD;
          -  Must be on stable anti-parkinsonian medications for 28 days prior to Informed Consent&#xD;
&#xD;
          -  Persistent disabling Parkinson's disease symptoms such as dyskinesias, motor&#xD;
             fluctuations, or disabling &quot;off&quot; periods despite optimal medical therapy&#xD;
&#xD;
          -  Be willing and able to comply with all visits and study related procedures (e.g.,&#xD;
             using the remote control, charging system, etc.).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any intracranial abnormality or medical condition that would contraindicate DBS&#xD;
             surgery&#xD;
&#xD;
          -  Have any significant psychiatric or cognitive condition likely to compromise the&#xD;
             subject's ability to comply with requirements of the study protocol (e.g. bipolar,&#xD;
             schizophrenia, mood disorder with psychotic features, cluster B personality disorders)&#xD;
&#xD;
          -  Any current drug or alcohol abuse, as determined by the investigator&#xD;
&#xD;
          -  Any history of recurrent or unprovoked seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roshini Jain</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Neuromodulation Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cleo Mertz</last_name>
    <phone>+32 479 76 71 56</phone>
    <email>Cleo.Mertz@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Keesey</last_name>
    <email>diane.keesey@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Berlin, Charite Virchow Standort, Wedding</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific Clinical Research</last_name>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koeln</name>
      <address>
        <city>Koeln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific Clinical Research</last_name>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>WÃ¼rzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific Clinical Research</last_name>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific Clinical Research</last_name>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific Clinical Research</last_name>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Georges Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific Clinical Research</last_name>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Brain Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

